• 1
    Forestier F, Sole Y, Aiach M, Alhenc Gelas M, Daffos F. Absence of transplacental passage of fragmin (Kabi) during the second and third trimesters of pregnancy. Thromb Haemost 1992; 67: 180181.
  • 2
    Omri A, Delaloye JF, Anderson H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989; 61: 5556.
  • 3
    Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652656.
  • 4
    Sturridge F, De Swiet M, Letsky E. The use of low molecular weight heparin for thromboprophylaxis in pregnancy. Br J Obstet Gynaecol 1994; 101: 6971.
  • 5
    Bertoli D & Borelli G. Peri- and postnatal teratology and reproductive studies of a low molecular weight heparin in rats. Arzneimittelforschung 1986; 36: 12601263.
  • 6
    O'Reilly RA. Anticoagulant, antithrombotic, and thrombolytic drugs. In GilmanAG, GoodmanLS, GilmanA, eds. The Pharmacological Basis of Therapeutics. 6th edn. New York: MacMillan, 1980: 13471366.
  • 7
    Harenberg J, Leber G, Zimmermann R, Schmidt W. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Schwangerschaft. Geburtshilfe Frauenheilkd 1987; 47: 1518.
  • 8
    Dryjski M, Schneider DE, Mojaverian P, Be-Sheng Kuo Bjornsson TD. Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. Br J Clin Pharmacol 1989; & 28: 188192.
  • 9
    Larsen AK, Lund DP, Langer R, Folkman J. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci USA 1986; 83: 29642968.